XYL - Xylem Inc.

NYSE - NYSE Delayed Price. Currency in USD
67.90
+1.90 (+2.88%)
At close: 4:00PM EDT

67.90 0.00 (0.00%)
After hours: 4:24PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close66.00
Open66.70
Bid67.80 x 1300
Ask67.85 x 800
Day's Range66.25 - 68.34
52 Week Range54.62 - 89.34
Volume1,110,767
Avg. Volume1,493,643
Market Cap12.216B
Beta (5Y Monthly)1.07
PE Ratio (TTM)34.12
EPS (TTM)1.99
Earnings DateJul 30, 2020
Forward Dividend & Yield1.04 (1.58%)
Ex-Dividend DateMay 27, 2020
1y Target Est64.21
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Thomson Reuters StreetEvents

    Edited Transcript of XYL earnings conference call or presentation 5-May-20 1:00pm GMT

    Q1 2020 Xylem Inc Earnings Call

  • Xylem Inc. Declares Second Quarter Dividend of 26 Cents Per Share
    Business Wire

    Xylem Inc. Declares Second Quarter Dividend of 26 Cents Per Share

    Xylem Inc. Declares Second Quarter Dividend of 26 Cents Per Share

  • Xylem and UNICEF partner to provide COVID-19 relief and safe water for children, families in vulnerable communities around the world
    Business Wire

    Xylem and UNICEF partner to provide COVID-19 relief and safe water for children, families in vulnerable communities around the world

    Xylem and UNICEF partner to provide COVID-19 relief and safe water to communities around the world

  • Xylem Inc (XYL) Q1 2020 Earnings Call Transcript
    Motley Fool

    Xylem Inc (XYL) Q1 2020 Earnings Call Transcript

    XYL earnings call for the period ending March 31, 2020.

  • Xylem (XYL) Q1 Earnings Lag Estimates, Organic View Weak
    Zacks

    Xylem (XYL) Q1 Earnings Lag Estimates, Organic View Weak

    Xylem's (XYL) Q1 results reflect the adverse impacts of the coronavirus outbreak, a fall in margins and forex woes. Organic sales in Q2 are expected to reflect the uncertainties as well.

  • Xylem (XYL) Misses Q1 Earnings and Revenue Estimates
    Zacks

    Xylem (XYL) Misses Q1 Earnings and Revenue Estimates

    Xylem (XYL) delivered earnings and revenue surprises of -37.84% and -1.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Xylem Reports First Quarter 2020 Results
    Business Wire

    Xylem Reports First Quarter 2020 Results

    Xylem Reports First Quarter 2020 Results

  • Xylem extends global community grants program to support COVID-19 response
    Business Wire

    Xylem extends global community grants program to support COVID-19 response

    Xylem extends global community grants program to support COVID-19 response

  • Xylem partners with Americares for COVID-19 response and global health work
    Business Wire

    Xylem partners with Americares for COVID-19 response and global health work

    Xylem partners with Americares for COVID-19 response and global health work

  • Xylem to release first quarter 2020 financial results on May 5, 2020
    Business Wire

    Xylem to release first quarter 2020 financial results on May 5, 2020

    Xylem to release first quarter 2020 financial results on May 5, 2020

  • Goldman Sachs: 2 S&P 500 Stocks to Buy (And 1 to Avoid)
    TipRanks

    Goldman Sachs: 2 S&P 500 Stocks to Buy (And 1 to Avoid)

    Since the virus scare began, and during the economy’s swing from bull to bear, investment bank Goldman Sachs has kept its finger on the pulse of the stock market. Fortunately for investors, the bank predicts that the S&P 500 won’t register new lows, and has been advising clients to ‘buy the dip.’Silvia Ardagna, of the GS Private Wealth Management investment strategy group, noted, “Our own advice to clients is that right now is a good time to get back into markets and take advantage of the decline in equity markets to position for the rebound.”Ardagna and her team see a recession developing for 1H20, caused by the economic impact of coronavirus and the measures taken to combat the epidemic, but remain “positively impressed” by the response from policymakers. Predicting a V-shaped recovery, she believes that a strong recovery is likely in the second half of the year.We’ve looked into Goldman's recent calls, and using the TipRanks database, we’ve chosen two of the firm's recent stock picks, and one that demands more caution from investors. Let’s take a closer look.CSX Corporation (CSX)We’ll start in the transportation industry, where CSX, a holding company, operates through its subsidiaries. The company’s rail transport subsidiaries are located primarily in the eastern US (the company’s name is derived from the old Chesapeake and Ohio Railroad), while other services, including container shipping, barge transport, and contract logistics are provided worldwide.Heading into the coronavirus disruptions, CSX started out with a strong position. The company reported 99 cents EPS in the fourth quarter, beating the estimate by 2%, the $2.9 billion in quarterly revenue was also over the forecast. But what about the current coronavirus quarter?Covering this stock for Goldman Sachs, analyst Jordan Alliger writes, “While the upcoming quarters certainly bring elevated EPS risk … we believe CSX on a 12-month basis offers solid risk/reward… The combination of valuation support, operational strength, and liquidity, plus cyclical positioning for eventual recovery makes overweight exposure to rails desirable upon virus containment.”Alliger backs up his long-term optimism with a rating upgrade, bumping CSX shares from Neutral to Buy. His $75 price target suggests an upside potential of 25% for the coming year. (To watch Alliger’s track record, click here)Overall, CSX holds a Moderate Buy rating from the analyst consensus. This is a based on a 9-8 split among the recent reviews of Buys versus Holds. Shares are selling for $60 now, and the average price target of $69 implies 14.5% upside from current levels. (See CSX stock analysis on TipRanks.)Henry Schein, Inc. (HSIC)Next up, we move to the healthcare industry, a segment that is, in time, sure to see a positive bounce due to the coronavirus. As efforts expand to contain and control the spread of the COVID-19 disease, healthcare and its various support services will be in high demand.Henry Schein distributes healthcare products and services in over 30 countries. The company offers services for business, clinical, technology, and supply chain solutions, especially tailored to the medical and dental industries.Like CSX above, HSIC started 2020 – and faced the coronavirus epidemic – following strong Q4 results. Revenues came in at $2.67 billion, matching the forecast and up 8.1% year-over-year, and the EPS of 97 cents was up 8.9% yoy and beat the forecast by 6.6%. The company’s Medial and Technology/Value-added services led the revenue gains, growing 15% and 20% respectively. Even better, for the current climate, HSIC finished 2019 with $106.1 million in cash on hand, up nearly $50 million from year before.Goldman Sachs analyst Nathan Rich lays out the case for optimism here: “We think HSIC faces lower earnings risk than peers from the COVID n outbreak and its business may be quicker to recover... HSIC’s Medical segment should benefit from the distribution of COVID tests, which could help to mitigate the impact of lower dental/physician office traffic.” In other words, Henry Schein’s leading position in the healthcare industry during a time of pandemic crisis, place it in a strong position for future growth.Rich’s Buy rating on the stock represents an upgrade from Neutral, and his $59 price target implies room for 13% growth in the coming 12 months. (To watch Rich’s track record, click here)Wall Street tends to agree with the analyst's confidence on the healthcare player, considering TipRanks analytics reveal HSIC as a Strong Buy. Out of 4 analysts tracked in the last 3 months, 3 are bullish on Henry Schein stock while 1 remains sidelined. With a return potential of nearly 25%, the stock's consensus target price stands at $65. (See Henry Schein stock analysis onTipRanks.)Xylem, Inc. (XYL)Not all stocks are so well positioned for gains, even if they inhabit essential industries. Xylem is a player in the water and wastewater niche, providing services that address the full water cycle, from collection to distribution to its return to the environment. Xylem’s products include pumps, valves, heat exchangers, dispensing equipment, and treatment and testing equipment.Water is essential to life, and reputable performers in the water industry can usually build a solid niche. Xylem finished 2019 with $5.25 billion in revenues, net income of $401 million, and a strong balance sheet including $1.7 billion on hand in liquid assets and available credit.But in a flashing warning sign for investors, Xylem on March 31 withdrew its 2020 guidance, citing the impact of COVID-19. The company has previously indicated a 1% to 2% revenue loss in Q1 when the virus first began to spread – but as it became an epidemic, and then spread worldwide, Xylem saw the impact on business and supply chains as more disruptive. Revising guidance would make sense in that environment – but Xylem simply withdrew its forecast without replacing it, leaving investors up in the air.Brian Lee, in his coverage of the stock for Goldman Sachs, sees a possible reason for the company’s guidance move – a reason that also prompts him to downgrade this stock from Neutral to Sell. He writes, “Based on our sensitivity analysis framework across our water coverage, we see greater downside risk to XYL’s fundamentals in light of the COVID-19 headwinds, largely given the company’s limited recurring revenue exposure… [this] leaves the company more exposed to the potential downturn in new demand…”Lee’s Sell rating is accompanied by a lower price target of $56, indicating his view that the stock will slip by 16% this year. (To watch Lee’s track record, click here)All in all, Xylem’s Hold rating from the analyst consensus is based on 11 recent reviews, including a single Buy, 8 Holds, and 2 Sells. Wall Street is not sanguine about this stock. Shares are trading at $66.68, while the $68.22 average price target suggests an upside potential of merely 2%. (See Xylem stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Xylem withdraws first quarter and full-year guidance, continues serving customers on front lines of essential services
    Business Wire

    Xylem withdraws first quarter and full-year guidance, continues serving customers on front lines of essential services

    Xylem withdraws first quarter and full-year guidance, continues serving customers

  • Thomson Reuters StreetEvents

    Edited Transcript of XYL earnings conference call or presentation 2-May-19 1:00pm GMT

    Q1 2019 Xylem Inc Earnings Call

  • Hedge Funds Were Betting On Xylem Inc (XYL) Before The Coronavirus
    Insider Monkey

    Hedge Funds Were Betting On Xylem Inc (XYL) Before The Coronavirus

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • Is It Too Late To Consider Buying Xylem Inc. (NYSE:XYL)?
    Simply Wall St.

    Is It Too Late To Consider Buying Xylem Inc. (NYSE:XYL)?

    Let's talk about the popular Xylem Inc. (NYSE:XYL). The company's shares received a lot of attention from a...

  • 3 Stocks That Have Grown Sales Fast
    GuruFocus.com

    3 Stocks That Have Grown Sales Fast

    Their five-year sales growth ratios top the US market Continue reading...

  • Xylem postpones investor day in support of broader efforts to combat the spread of COVID-19
    Business Wire

    Xylem postpones investor day in support of broader efforts to combat the spread of COVID-19

    Xylem postpones investor day in support of broader efforts to combat the spread of COVID-19

  • Xylem appoints two new commercial and segment leaders to executive team
    Business Wire

    Xylem appoints two new commercial and segment leaders to executive team

    Xylem appoints two new commercial and segment leaders to executive team

  • Xylem Stock Keeps Its Head Above Water Amid Market Slump
    Investor's Business Daily

    Xylem Stock Keeps Its Head Above Water Amid Market Slump

    Xylem shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

  • GuruFocus.com

    5 Companies Reach 52-Week Highs

    As of late, these companies have managed to reach their 52-week highs Continue reading...

  • Why You Might Be Interested In Xylem Inc. (NYSE:XYL) For Its Upcoming Dividend
    Simply Wall St.

    Why You Might Be Interested In Xylem Inc. (NYSE:XYL) For Its Upcoming Dividend

    Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Xylem Inc...

  • Thomson Reuters StreetEvents

    Edited Transcript of XYL earnings conference call or presentation 6-Feb-20 2:00pm GMT

    Q4 2019 Xylem Inc Earnings Call

  • GuruFocus.com

    Stock Market in the Green on Thursday

    Bristol-Myers Squibb rises on 4th-quarter results Continue reading...

  • Xylem (XYL) Matches Q4 Earnings Estimates
    Zacks

    Xylem (XYL) Matches Q4 Earnings Estimates

    Xylem (XYL) delivered earnings and revenue surprises of 0.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?